While tirzepatide often shows superior results in trials, its not a one-size-fits-all solution
Market Restraints Drug Pricing, Supply Constraints, Gastrointestinal Tolerability, and Compounding Disruption Limit GLP-1 Market Scaling Drug pricing and affordability remain the most impactful near-term restraints for the GLP-1 Weight Loss Drug Market through 2030
Ready to get serious about weight loss
A second consequence of the use of GLP-1R agonists may be the higher-than-expected blood ethanol levels
Stay Informed Key dates to watch in 2026: TRIUMPH-1 and TRIUMPH-2 results (mid-2026), head-to-head retatrutide vs tirzepatide results (December 2026), and any NDA filing announcements from Eli Lilly
"That person may be able to be more active after losing the weight, perhaps they're sleeping better and having fewer sleep apnea events (which have been linked as a risk factor for type two diabetes)